TORONTO, April 11, 2025--(BUSINESS WIRE)--Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP) ("Predictmedix" or the "Company"), a leading provider in AI-driven health and safety solutions, welcomes the U.S. Food and Drug Administration’s (FDA) groundbreaking move to phase out mandatory animal testing in drug development. As the pharmaceutical and biotech industries pivot toward more ethical and technologically advanced methodologies, Predictmedix’s Smart Health AI Stations stand out as a scalable, non-invasive, and human-centric alternative for preclinical and clinical evaluations.
This regulatory shift signals a new era in drug development—one that emphasizes innovation, speed, and safety in human trials. Predictmedix’s proprietary AI platform, capable of real-time physiological and cognitive assessment, offers a powerful solution for pharmaceutical companies seeking to accelerate human-based research while ensuring rigorous data integrity and compliance.
"Our Smart Health AI Stations are built for this future," said Dr. Rahul Kushwah, COO of Predictmedix AI. "As the FDA reshapes the regulatory landscape, our technology bridges the gap between ethical standards and scientific rigor—making it easier for drug developers to conduct early-stage evaluations on human subjects safely and at scale."
Deployed across hospitals, research institutions, and occupational health settings, the AI-powered stations continuously monitor vitals, impairment, fatigue, and infection markers using advanced algorithms. The technology reduces dependency on invasive procedures and offers high-throughput data collection essential for modern clinical trials.
Predictmedix AI’s technology serves as an alternative to animal models by analyzing real-time human biomarkers to predict physiological responses. Traditional drug testing relies on animal models to estimate how a substance will affect humans, but biological differences between species often limit their accuracy. In contrast, Predictmedix AI uses advanced machine learning and sensor technology to assess key human health indicators—such as heart rate, temperature, blood pressure, respiration rate and other vital signs—providing direct, human-relevant data for evaluating drug responses. This approach reduces reliance on animal testing while offering more precise insights into human physiology, ultimately improving drug development and safety assessments. With over 500,000 scans conducted, the platform has been rigorously validated, achieving up to 95% accuracy in detecting vital signs, ensuring reliable and precise health assessments.
Core Advantages of Predictmedix’s Smart Health AI Stations:
Scalable and Modular – Easily deployable across trial sites or research institutions
Non-Invasive and Contactless – Enhancing patient compliance and safety
Compliant and Secure – Built with data privacy and regulatory standards in mind
Predictmedix AI is in active discussions with pharmaceutical and clinical research organizations to integrate its AI health screening stations into decentralized and adaptive trial frameworks, positioning itself as a foundational player in the post-animal testing era.
About Predictmedix AI Inc. Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company’s Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI’s proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.
Caution Regarding Forward-Looking Information: This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
Disclaimer: The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
